Jefferies downgraded Amicus (FOLD) to Hold from Buy with a price target of $14.50, down from $16. Proxy documents show the company did receive extensive pharma takeover interest beyond BioMarin, the analyst tells investors in a research note. As such, Jefferies does not expect additional takeover bids for Amicus.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- BioMarin upgraded to Buy from Hold at Canaccord
- Amicus downgraded to Neutral from Buy at Guggenheim
- Midday Fly By: SoftBank buying DigitalBridge, Verisk drops AccuLynx deal
- Amicus Therapeutics: Acquisition Premium Caps Upside, Driving Neutral Stance at BioMarin’s $14.50 Offer Price
- Amicus downgraded to Market Perform from Outperform at Leerink